D. Boral Capital Reaffirms Buy Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They currently have a $29.00 target price on the stock.

Other analysts have also issued reports about the stock. HC Wainwright lowered their price objective on shares of Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, November 11th. EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Price Performance

NASDAQ:IMNN opened at $0.83 on Monday. Imunon has a 1-year low of $0.48 and a 1-year high of $3.65. The company has a 50-day moving average of $0.93 and a 200 day moving average of $1.14. The firm has a market cap of $12.02 million, a PE ratio of -0.44 and a beta of 2.14.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.